NCT00005632View on ClinicalTrials.gov

Vaccine Therapy Plus QS21 in Treating Patients With Prostate Cancer

PHASE1CompletedINTERVENTIONAL
Enrollment

27

Participants

Timeline

Start Date

June 30, 1999

Primary Completion Date

March 31, 2009

Study Completion Date

March 31, 2009

Conditions
Prostate Cancer
Interventions
BIOLOGICAL

MUC1-KLH vaccine/QS21

Trial Locations (1)

10021

Memorial Sloan-Kettering Cancer Center, New York

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

Memorial Sloan Kettering Cancer Center

OTHER

NCT00005632 - Vaccine Therapy Plus QS21 in Treating Patients With Prostate Cancer | Biotech Hunter | Biotech Hunter